RECURSION PHARMACEUTICALS-A (RXRX) Stock Overview
USA - NASDAQ:RXRX - US75629V1044 - Common Stock
RXRX Key Statistics, Chart & Performance
The current stock price of RXRX is 5.87 USD. In the past month the price increased by 15.1%. In the past year, price decreased by -8.28%.
RXRX Latest News, Press Relases and Analysis
RXRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.26 | 397.72B | ||
| AMGN | AMGEN INC | 13.38 | 157.08B | ||
| GILD | GILEAD SCIENCES INC | 15.31 | 147.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.63 | 106.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.51 | 69.20B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.13B | ||
| ARGX | ARGENX SE - ADR | 89.25 | 50.61B | ||
| INSM | INSMED INC | N/A | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.58B | ||
| NTRA | NATERA INC | N/A | 26.46B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.24 | 21.68B |
Related stock screener links
About RXRX
Company Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 840 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Company Info
RECURSION PHARMACEUTICALS-A
41S Rio Grande Street
Salt Lake City UTAH 84101 US
CEO: Christopher Gibson
Employees: 840
Phone: 13852690203
RECURSION PHARMACEUTICALS-A / RXRX FAQ
What does RECURSION PHARMACEUTICALS-A do?
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 840 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Can you provide the latest stock price for RECURSION PHARMACEUTICALS-A?
The current stock price of RXRX is 5.87 USD. The price decreased by -0.68% in the last trading session.
What is the dividend status of RECURSION PHARMACEUTICALS-A?
RXRX does not pay a dividend.
What is the ChartMill rating of RECURSION PHARMACEUTICALS-A stock?
RXRX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of RECURSION PHARMACEUTICALS-A (RXRX)?
RECURSION PHARMACEUTICALS-A (RXRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.78).
Can you provide the growth outlook for RECURSION PHARMACEUTICALS-A?
The Revenue of RECURSION PHARMACEUTICALS-A (RXRX) is expected to grow by 1.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for RXRX stock?
You can find the ownership structure of RECURSION PHARMACEUTICALS-A (RXRX) on the Ownership tab.
RXRX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RXRX. When comparing the yearly performance of all stocks, RXRX is a bad performer in the overall market: 72.21% of all stocks are doing better.
RXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RXRX. Both the profitability and financial health of RXRX have multiple concerns.
RXRX Financial Highlights
Over the last trailing twelve months RXRX reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS decreased by -8.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.84% | ||
| ROE | -70.62% | ||
| Debt/Equity | 0.02 |
RXRX Forecast & Estimates
14 analysts have analysed RXRX and the average price target is 6.6 USD. This implies a price increase of 12.37% is expected in the next year compared to the current price of 5.87.
For the next year, analysts expect an EPS growth of 1.46% and a revenue growth 1.25% for RXRX